- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06500702
En studie for å evaluere effektiviteten og sikkerheten til Frexalimab, SAR442970 eller Rilzabrutinib hos deltakere i alderen 16 til 75 år med primær fokal segmentell glomerulosklerose eller minimal endringssykdom (RESULT)
En parallellgruppebehandling, fase 2a, multisenter, randomisert, dobbeltblind, placebokontrollert paraplystudie for å evaluere effektiviteten og sikkerheten til Frexalimab, SAR442970 og Rilzabrutinib hos deltakere i alderen 16 til 75 år med primær fokalulos segmental glomerulose (FSGSclmental glomerulose) eller Minimal Change Disease (MCD)
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years.
Study details for each participant include:
The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Trial Transparency email recommended (Toll free for US & Canada)
- Telefonnummer: option 6 800-633-1610
- E-post: contact-us@sanofi.com
Studiesteder
-
-
-
Buenos Aires, Argentina, 1431
- Rekruttering
- Investigational Site Number : 0320001
-
Córdoba, Argentina, 5016
- Rekruttering
- Investigational Site Number : 0320002
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2605
- Rekruttering
- Investigational Site Number : 0360003
-
-
Victoria
-
Parkville, Victoria, Australia, 3050
- Rekruttering
- Investigational Site Number : 0360001
-
-
-
-
-
São Paulo, Brasil, 05403-000
- Rekruttering
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001
-
São Paulo, Brasil, 04038-002
- Rekruttering
- Hospital do Rim e Hipertensão- Site Number : 0760002
-
-
São Paulo
-
Botucatu, São Paulo, Brasil, 18618-970
- Rekruttering
- Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760004
-
São Paulo, São Paulo, Brasil, 01139-000
- Rekruttering
- Synvia Clinical- Site Number : 0760005
-
-
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Rekruttering
- Investigational Site Number : 1240002
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Rekruttering
- Investigational Site Number : 1240001
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- Investigational Site Number : 1240005
-
Québec, Quebec, Canada, G1R 2J6
- Rekruttering
- Investigational Site Number : 1240006
-
-
-
-
La Araucanía
-
Temuco, La Araucanía, Chile, 4781151
- Rekruttering
- Investigational Site Number : 1520003
-
-
Reg Metropolitana de Santiago
-
Santiago, Reg Metropolitana de Santiago, Chile, 8330034
- Rekruttering
- Investigational Site Number : 1520002
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Rekruttering
- University of Alabama -The Kirklin Clinic- Site Number : 8400007
-
-
California
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California Irvine Medical Center- Site Number : 8400015
-
San Francisco, California, Forente stater, 94143
- Rekruttering
- University of California San Francisco - Parnassus Heights- Site Number : 8400012
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- University Of South Florida - Parent- Site Number : 8400025
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory Children's Center- Site Number : 8400020
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern Memorial Hospital- Site Number : 8400014
-
Hinsdale, Illinois, Forente stater, 60521
- Rekruttering
- Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan Health System - Ann Arbor- Site Number : 8400010
-
-
Minnesota
-
Edina, Minnesota, Forente stater, 55435
- Rekruttering
- InterMed Consultants - Edina Clinic- Site Number : 8400019
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89107
- Aktiv, ikke rekrutterende
- DaVita Clinical Research - Las Vegas - North Rainbow Boulevard- Site Number : 8400018
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- Rekruttering
- Renal Medicine Associates- Site Number : 8400028
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University Irving Medical Center- Site Number : 8400001
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- The Children's Hospital at Montefiore- Site Number : 8400027
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- UNC Kidney Center- Site Number : 8400021
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland- Site Number : 8400029
-
-
Texas
-
Dallas, Texas, Forente stater, 75204
- Rekruttering
- Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024
-
El Paso, Texas, Forente stater, 79902
- Rekruttering
- El Paso Kidney Specialists- Site Number : 8400005
-
Houston, Texas, Forente stater, 77054
- Rekruttering
- Prolato Clinical Research Center- Site Number : 8400016
-
-
-
-
-
Créteil, Frankrike, 94010
- Rekruttering
- Investigational Site Number : 2500002
-
Paris, Frankrike, 75015
- Rekruttering
- Investigational Site Number : 2500001
-
-
-
-
-
Athens, Hellas, 115 27
- Rekruttering
- Investigational Site Number : 3000002
-
Heraklion, Hellas, 711 10
- Rekruttering
- Investigational Site Number : 3000001
-
Ioannina, Hellas, 455 00
- Rekruttering
- Investigational Site Number : 3000003
-
-
-
-
-
Brescia, Italia, 25123
- Rekruttering
- Investigational Site Number : 3800001
-
-
Firenze
-
Florence, Firenze, Italia, 50134
- Rekruttering
- Investigational Site Number : 3800002
-
-
Milano
-
Monza, Milano, Italia, 20900
- Rekruttering
- Investigational Site Number : 3800004
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Rekruttering
- Investigational Site Number : 3800003
-
-
-
-
-
Beijing, Kina, 100034
- Rekruttering
- Investigational Site Number : 1560001
-
Chengdu, Kina, 610072
- Rekruttering
- Investigational Site Number : 1560003
-
Shanghai, Kina, 200080
- Fullført
- Investigational Site Number : 1560004
-
-
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 14080
- Rekruttering
- Investigational Site Number : 4840001
-
Mexico City, Mexico City, Mexico, 06720
- Rekruttering
- Investigational Site Number : 4840005
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- Rekruttering
- Investigational Site Number : 4840003
-
-
-
-
-
Amsterdam, Nederland, 1105 AZ
- Rekruttering
- Investigational Site Number : 5280001
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 60-780
- Rekruttering
- Investigational Site Number : 6160004
-
-
Lódzkie
-
Lodz, Lódzkie, Polen, 02-213
- Rekruttering
- Investigational Site Number : 6160001
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polen, 45-418
- Rekruttering
- Investigational Site Number : 6160002
-
-
-
-
-
Carnaxide, Portugal, 2790-134
- Rekruttering
- Investigational Site Number : 6200004
-
Lisbon, Portugal, 1050-099
- Rekruttering
- Investigational Site Number : 6200003
-
Matosinhos Municipality, Portugal, 4464-513
- Fullført
- Investigational Site Number : 6200001
-
Porto, Portugal, 4434-502
- Rekruttering
- Investigational Site Number : 6200002
-
-
-
-
-
Banská Bystrica, Slovakia, 975 17
- Rekruttering
- Investigational Site Number : 7030003
-
Bratislava - Kramare, Slovakia, 831 01
- Rekruttering
- Investigational Site Number : 7030004
-
Martin, Slovakia, 036 01
- Rekruttering
- Investigational Site Number : 7030001
-
-
-
-
-
Córdoba, Spania, 14004
- Rekruttering
- Investigational Site Number : 7240002
-
Madrid, Spania, 28007
- Rekruttering
- Investigational Site Number : 7240008
-
Madrid, Spania, 28040
- Rekruttering
- Investigational Site Number : 7240007
-
Valencia, Spania, 46026
- Fullført
- Investigational Site Number : 7240003
-
-
Andalusia
-
Seville, Andalusia, Spania, 41013
- Rekruttering
- Investigational Site Number : 7240005
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Spania, 08035
- Rekruttering
- Investigational Site Number : 7240001
-
Barcelona, Catalunya [Cataluña], Spania, 08025
- Fullført
- Investigational Site Number : 7240004
-
-
Navarre
-
Pamplona, Navarre, Spania, 31008
- Rekruttering
- Investigational Site Number : 7240009
-
-
-
-
Leicestershire
-
Leicester, Leicestershire, Storbritannia, LE5 4PW
- Rekruttering
- Investigational Site Number : 8260001
-
-
Manchester
-
Salford, Manchester, Storbritannia, M6 8HD
- Rekruttering
- Investigational Site Number : 8260004
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannia, OX3 7LE
- Rekruttering
- Investigational Site Number : 8260005
-
-
-
-
-
Taichung, Taiwan, 404
- Rekruttering
- Investigational Site Number : 1580001
-
Taipei, Taiwan, 100
- Rekruttering
- Investigational Site Number : 1580002
-
-
-
-
-
Olomouc, Tsjekkia, 779 00
- Rekruttering
- Investigational Site Number : 2030002
-
Prague, Tsjekkia, 128 08
- Rekruttering
- Investigational Site Number : 2030001
-
-
-
-
-
Kayseri, Tyrkia (Türkiye), 38039
- Rekruttering
- Investigational Site Number : 7920002
-
İzmit, Tyrkia (Türkiye), 41001
- Rekruttering
- Investigational Site Number : 7920001
-
-
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Investigational Site Number : 2760002
-
Dresden, Tyskland, 01307
- Rekruttering
- Investigational Site Number : 2760006
-
Hanover, Tyskland, 30625
- Rekruttering
- Investigational Site Number : 2760003
-
-
-
-
-
Budapest, Ungarn, 1085
- Rekruttering
- Investigational Site Number : 3480001
-
Pécs, Ungarn, 7624
- Rekruttering
- Investigational Site Number : 3480005
-
Szeged, Ungarn, 6725
- Rekruttering
- Investigational Site Number : 3480006
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Biopsy report indicative of primary FSGS or MCD, with supportive clinical presentation per Investigator's judgement.
- UPCR ≥3 g/g at screening, or ≥ 1.5 g/g in those with eGFR ≥ 60 mL/min/1.73 m2.
- eGFR ≥45 mL/min/1.73 m^2 at screening.
- Documented history of UPCR or UACR (or 24-hour urine protein or 24-hour urine albumin) reduction by >40% in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g or equivalent for UACR (or pre-treatment 24-hr urine protein was ≥3.5 g/day if 24-hour urine protein is used or equivalent for 24-hr urine albumin if 24-hour urine albumin is used).
- ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior to randomization.
- For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting RAAS inhibitors or changing the dose will not be allowed during the double-blind or OLE treatment period.
- For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting SGLT2 inhibitor treatment or changing the dose will not be allowed during the double-blind or OLE treatment periods.
- Body weight within 45 to 120 kg (inclusive) at screening.
Exclusion Criteria:
- Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.
- Collapsing variant of FSGS.
- ESKD requiring dialysis or transplantation.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Matching placebo |
placebo treatment |
|
Eksperimentell: Frexalimab
Frexalimab active dose |
frexalimab treatment |
|
Eksperimentell: Brivekimig
Brivekimig active dose |
brivekimig treatment |
|
Eksperimentell: Rilzabrutinib
Rilzabrutinib active dose |
rilzabrutinib treatment |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prosentvis reduksjon i forholdet mellom protein og kreatinin i urin (UPCR)
Tidsramme: Fra baseline til uke 12
|
Fra baseline til uke 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasmakonsentrasjoner av frexalimab og rilzabrutinib og serumkonsentrasjoner av SAR442970
Tidsramme: Frem til uke 48
|
Frem til uke 48
|
|
|
Forekomst av anti-legemiddelantistoffer (ADA) mot frexalimab og SAR442970
Tidsramme: Frem til uke 48
|
Frem til uke 48
|
|
|
Percentage of participants achieving FSGS partial remission endpoint
Tidsramme: At Week 12
|
Defined as UPCR ≤1.5 g/g and >40 % reduction of UPCR from baseline |
At Week 12
|
|
Percentage of participants achieving CR
Tidsramme: At Week 12
|
Defined as UPCR ≤0.3 g/g |
At Week 12
|
|
Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events (SAEs), treatment-emergent adverse events of special interest (AESIs) and IMP discontinuation due to TEAEs during the study
Tidsramme: Treatment emergent period, up to Week 48
|
TEAEs, including clinically significant changes in vital signs, electrocardiogram [ECG], and laboratory evaluation |
Treatment emergent period, up to Week 48
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ACT18064
- 2024-511775-15 (Registeridentifikator: CTIS)
- U1111-1301-2676 (Registeridentifikator: WHO)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .